Background {#Sec1}
==========

In 2016, there were an estimated 10.4 million new tuberculosis (TB) cases across the globe, with India and followed by Indonesia, China, Philippines, Pakistan, Nigeria, and South Africa accounting for 64% of the total burden \[[@CR1], [@CR2]\]. Whilst global efforts aimed to combat tuberculosis (TB) have saved an estimated 53 million lives since 2000 and reduced the TB mortality rate by 37%, according to the Global TB Report 2018, TB remains the infectious disease which caused the highest number of deaths in 2017 \[[@CR2], [@CR3]\].

Concurrently, diabetes mellitus (DM) is burgeoning as a global chronic health condition, which can be attributed to increases in obesity and changing patterns of diet and physical activity as well as ageing \[[@CR3]\]. The global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014, and by 2030, its prevalence is expected to increase by 50% \[[@CR4]\].

As is the case with TB, three in four diabetic patients live in low-income countries \[[@CR5], [@CR6]\], and according to the World Health Organization (WHO), in 2015, there were an estimated 1.6 million deaths that could be attributed to diabetes \[[@CR4]\]. This is all the more worrisome as DM is in its own right a risk factor for cardiovascular disease (CVD), an umbrella term for a set of clinical conditions that affect 13 million people worldwide, accounting for 25% of all deaths \[[@CR7]\]. Previous studies have shown that enhanced DM case management and improved blood glucose control can lead to improved TB treatment outcomes \[[@CR8], [@CR9]\]. As an added benefit, this helps to alleviate the economic burden within the healthcare systems on a global level.

Whilst a meta-analysis has shown that DM increases the risk of TB threefold compared to the non-diabetic population \[[@CR10]\], and a pooled overall prevalence of tuberculosis in diabetic patients was calculated to be 4.72% (95% CI 3.62--5.83%) \[[@CR11]\], there is still a lack of knowledge whether TB can predispose an individual to DM. Infections, including TB, often worsen glycaemic control in diabetic patients \[[@CR12]\]. Several cross-sectional studies have reported an association between TB outcome and the presence of hyperglycaemia \[[@CR13], [@CR14]\]. The transitory hyperglycaemia is likely to be of multifactorial aetiology and may be explained by the occurrence of early phase hyperglycaemia, induced by rifampicin administration \[[@CR15], [@CR16]\], hyperglycaemia that normally accompanies corticosteroid administration \[[@CR17]\], or stress hyperglycaemia ensuing from an intricate interplay between disturbed cytokine and hormone production, resulting in excessive hepatic glucose production and insulin resistance \[[@CR18]\].

Some studies suggest that TB can even cause diabetes in those not previously known to be diabetic \[[@CR19]--[@CR21]\]. In persons with prolonged glucose impairment, this may set in motion a vicious cycle, in which poorly controlled diabetes might in turn augment the severity of infections \[[@CR22]\] and the risk of MDR TB and cardiovascular disease.

Due to the worsening of DM and TB in low- and middle-income countries, the WHO and the International Union Against Tuberculosis and Lung Disease (IUATLD) support a collaborative framework that recommends bidirectional screening including testing for TB among people with DM \[[@CR23]\]. The WHO recommends screening for DM at the start of TB treatment; however, little is known which patients are at risk for developing DM and who would benefit from a more regular follow-up.

We aim to build on the literature review by Magee et al. \[[@CR24]\] on the epidemiology of intransient hyperglycaemia in TB patients with previously undiagnosed DM 2 individuals by performing a systematic review to synthesise the literature on the epidemiology of stress-induced hyperglycaemia with no date limit. Secondly, we will synthesise literature on risk factor for the above progression. We will then quantify these relationships using a meta-analysis. Both our narrative review and meta-analysis will allow us to identify clinical, epidemiological, and public health research gaps. Our protocol has been registered with PROSPERO (CRD42019118173; <https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=118173>).

Methods {#Sec2}
=======

Literature search strategy {#Sec3}
--------------------------

Our search strategy, selection of publications, and reporting of results for the review will be conducted in accordance with the PRISMA guidelines \[[@CR25]\]. The domains of the search terms are Tuberculosis AND hyperglycaemia OR Diabetes Mellitus. We will systematically search relevant studies in the following electronic databases: PubMed, EMBASE, PROQUEST, and SCOPUS without any language restrictions. Reference lists of all retrieved articles will be checked to identify further eligible publications.

Eligibility criteria {#Sec4}
--------------------

For eligibility, only peer-reviewed publications will be included. Eligible studies should report on TB-induced hyperglycaemia in all individuals irrespective of their age and have outcomes measured prospectively more than once. Retrospective case control studies where DM or pre-DM are cases will be included. In addition, the systematic review will report on risk factors for persistent TB-induced hyperglycaemia in newly detected DM. Case studies and cross-sectional studies will not be eligible.

Types of participants {#Sec5}
---------------------

Participants will be individuals newly diagnosed with DM following a previous TB diagnosis.

Outcome measures {#Sec6}
----------------

TB disease is defined by a positive chest x-ray and a sample of sputum \[[@CR26]\].

Overt, clinically manifested diabetes is preceded by prediabetes, a metabolic state characterised by elevated blood glucose levels in the range between normal glycaemia and diabetes, which is indicative of a risk for progression to type 2 diabetes.

Prediabetes is defined as impaired fasting glycemia (IFG; fasting plasma glucose (FPG) levels ≥ 100 mg/dl (5.6 mmol/l)) or impaired glucose tolerance (IGT; 2-h oral glucose tolerance test (OGTT) of ≥ 140 mg/dl (7.8 mmol/l)) \[[@CR27]\]. Independent risk factors for irreversible TB-induced hyperglycaemia in patients screened for DM following TB diagnosis will be reported.

Data extraction and management {#Sec7}
------------------------------

Two investigators (SM and JMF) will independently review and critically evaluate all identified studies (citations) for inclusion. SM and JMF will extract the data from eligible studies independently using Excel spreadsheet. SM and JMF will resolve the discrepancies on eligible studies and extracted data through a discussion involving SB and AD. The following items will be recorded: first author, study period, publication year, study type, study population, total sample size, age, method of diagnosis of TB, time of follow-up, glucose impairment status when diagnosed with TB, method used to ascertain persistent hyperglycaemia, risk factors for persistent DM, and confounders adjusted for. Whenever provided, outcome measures will be extracted along with its associated 95% confidence interval. In case of any missing information or need for clarification, respective study authors will be contacted via email.

Risk of bias in individual studies {#Sec8}
----------------------------------

Our systematic review will be conducted strictly in accordance with a protocol. We will assess the quality of the studies using the Newcastle-Ottawa Scale \[[@CR28]\]. The risk of bias will be ascertained by two reviewers, using the Cochrane Risk of Bias Tool \[[@CR29]\]. According to the Cochrane Risk of Bias Tool, each selected study will be graded as low, high, or unclear risk of bias across different types of bias. Assessment will be performed at the study level and will focus on selection, performance, detection, attrition, and reporting biases. The risk of bias for each included study will be taken into consideration during data synthesis. A sensitivity analyses, excluding the studies that will be graded as high or unclear risk of bias to determine the effect of removal on the results, will be performed.

Data analysis {#Sec9}
-------------

We will assess all identified articles for quality and perform quantitative synthesis of the information obtained from the eligible articles. In a situation whereby only a few (less than three) articles qualify for quantitative synthesis, we will then perform narrative synthesis.

As TB-induced hyperglycaemia is not rare, we will not be able to consider hazard ratios, risk ratios, and odds ratios as the same. If the data permit, we will classify studies according to their type of effect size and consequently pool these different effect size estimates. To pool effect sizes, we will be using STATA 15 and present the descriptive findings using tables and the meta-analysis findings using forest plots. Symmetry of funnel plots and Egger's test will be performed to explore the presence of selective reporting bias.

We will use random effect model to assess heterogeneity, as it is a conservative approach and data is expected to vary across studies. We will assess heterogeneity using the Desmordian-Laid test *I*^2^ (*I*^2^ ≥ 75%) which equates to high heterogeneity and visual inspection of the forest plot for inconsistencies in effect sizes and their confidence intervals. Meta-regression will be performed if data permit to analyse for sources of heterogeneity. In addition to a synthesis of literature, if heterogeneity permits, we will quantify this relationship using a meta-analysis.

Discussion {#Sec10}
==========

To the best of our knowledge, this systematic review and meta-analysis will provide the first narrative synthesis and quantitative estimate of the risk of irreversible TB-induced hyperglycaemia in those newly screened for DM upon TB diagnosis.

The pooled estimate will guide clinicians and policymakers in informing patients and governments about the risk of persistent hyperglycaemia in hitherto undiagnosed DM patients with TB and will likely aid the identification of patients at risk who will be required for more regular follow-up. Moreover, it will provide an estimate of the future global DM burden. Importantly, this systematic review will enable the identification of clinical, epidemiological, and public health gaps, thus outlining directions for further investigation.

The findings from the review will be disseminated in a peer-reviewed journal, and we will recommend or carry out research to bridge the identified gaps.

Strengths and limitations {#Sec11}
-------------------------

A major strength of our study is the comprehensive review within four major databases in order to include all potential articles. Anticipated limitations include the heterogeneity in the sample size of the retrieved studies and quality of the study design; therefore, it is difficult to give the right weight to the current evidence. Furthermore, heterogeneity in the sensitivity or specificity of screening methods may also render results less comparable. Also, there may be a lack of prospective studies with a clear strategy to deal with the loss to follow-up retrieved by the literature search.

Significant and positive research is more likely to be published, and the negative or insignificant findings will be less likely included in our systematic review due to the fact that they are not publicly available for inclusion. Additionally, our review will include studies published in English language. Consequently, several relevant unpublished or published studies in a language other than English may be been excluded.

DM

:   Diabetes mellitus

FPG

:   Fasting plasma glucose

HIV

:   Human immunodeficiency virus

IGT

:   Impaired glucose tolerance

IUATLD

:   International Union Against Tuberculosis and Lung Disease

MDR TB

:   Multidrug-resistant TB

TB

:   Tuberculosis

WHO

:   World Health Organization

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

SM is the lead author who conceived and drafted the protocol. NZ participated in the drafting of the protocol, and edited and validated the final version of the manuscript. JF validated and edited the final version of the manuscript. AD validated and edited the final version of the manuscript. SB validated and edited the final version of the manuscript. All authors read and approved the final manuscript.

The authors declare they did not receive funding.

N/A

N/A

N/A

The authors declare that they have no competing interests.
